<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01937234</url>
  </required_header>
  <id_info>
    <org_study_id>AFHSR-13-7-2013</org_study_id>
    <nct_id>NCT01937234</nct_id>
  </id_info>
  <brief_title>Use of an Antiemetic to Shorten the Length of Labor in Nulliparous Women</brief_title>
  <official_title>Use of an Antiemetic to Shorten the Length of Labor in Nulliparous Women, Exploring a Potential Role of an Old Drug</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Ain Shams University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Armed Forces Hospitals, Southern Region, Saudi Arabia</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Ain Shams University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Reducing the length of labor is a highly desirable goal of intrapartum care, both from a&#xD;
      perspective of maternal and fetal well-being , and for the providers of the birth services.&#xD;
      Avoiding a long , protracted labor entails shorter exposure to pain anxiety and stress and&#xD;
      would translate into a major improvement in maternal satisfaction with the child birth&#xD;
      experience.&#xD;
&#xD;
      The purpose of this study is to determine the effectiveness of metoclopramide for reducing&#xD;
      the duration of spontaneous labor among nulliparous women managed according to a standard&#xD;
      intrapartum protocol.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Women who will fulfill the study inclusion and exclusion criteria and agree to be included in&#xD;
      the study will be randomized assigned to receive either an intravenous injection of 10mg&#xD;
      metoclopramide (Group 1) or the same volume of placebo, i.e. 0.9% sodium chloride (Group2).&#xD;
      Randomization will be achieved using computer generated randomization sequences. Allocation&#xD;
      will be in 1:1 ratio. Record of group allocation will be maintained by a resident physician&#xD;
      whose responsibility is randomization and drawing up the injection, but has no direct&#xD;
      involvement in the intrapartum decision making.&#xD;
&#xD;
      After through history and physical examination, each participant will take the selected&#xD;
      medication slowly IV over 2 min, the assigned medication will be repeated every two hours for&#xD;
      a maximum of three doses.&#xD;
&#xD;
      Monitoring of fetal well-being and labor progress with Partographic representation will be&#xD;
      performed.&#xD;
&#xD;
      Management of labor will be according the labor and delivery standard protocol, if labor&#xD;
      dilatation will not progress appropriately, i.e. cervical dilatation rate of &lt;1cm/hour,&#xD;
      amniotomy will be performed if membranes are intact. Oxytocin augmentation will be considered&#xD;
      after rupture of membranes only if the cervix remains unchanged on two consecutive pelvic&#xD;
      examination conducted two hours apart. Oxytocin infusion will start with 5mIU/min and&#xD;
      increase by 5mIU/min every 15min to achieve seven contractions in 15 min, the maximal rate of&#xD;
      oxytocin being 30Miu/min.&#xD;
&#xD;
      The following parameters will be recorded for every patient:&#xD;
&#xD;
        -  Timing of metoclopramide or placebo injections&#xD;
&#xD;
        -  Timing of full dilatation of cervix&#xD;
&#xD;
        -  Duration of first stage of labor&#xD;
&#xD;
        -  Duration of second stage of labor&#xD;
&#xD;
        -  Duration of third stage of labor&#xD;
&#xD;
        -  Mode of delivery&#xD;
&#xD;
        -  Injection to delivery interval&#xD;
&#xD;
        -  Cervical dilatation rate&#xD;
&#xD;
        -  Neonatal condition at birth&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>July 2013</start_date>
  <completion_date type="Actual">September 2016</completion_date>
  <primary_completion_date type="Actual">July 2016</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Triple (Participant, Care Provider, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Cervical dilatation rate</measure>
    <time_frame>6 hours</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Duration of the first stage of labor</measure>
    <time_frame>6 hours</time_frame>
  </secondary_outcome>
  <other_outcome>
    <measure>Duration of the second stage of labor</measure>
    <time_frame>2 hours</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Duration of the third stage of labor</measure>
    <time_frame>1 hour</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Number of Participants with Adverse Events</measure>
    <time_frame>24 hours</time_frame>
    <description>Adverse effects of metoclopramide:&#xD;
Cardiovascular: heart block, bradycardia, heart failure, flushing, hyper or hypotension, supraventricular tachycardia.&#xD;
Central nervous system: Drowsiness, acute dystonic reactions, headache, dizziness, akathisia, confusion, depression, hallucinations, Parkinsonian-like symptoms, suicidal ideation, seizure, tardive dyskinesia&#xD;
Dermatologic: Angioneurotic edema, rash, urticaria&#xD;
Gastrointestinal: Nausea, vomiting, diarrhea&#xD;
Respiratory: Bronchospasm, laryngeal edema (rare), laryngospasm (rare)</description>
  </other_outcome>
  <other_outcome>
    <measure>Apgar score</measure>
    <time_frame>10 minutes</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Meconium stained liquor</measure>
    <time_frame>6 hours</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Neonatal intensive care unit admission rate</measure>
    <time_frame>24 hours</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Rate of vaginal delivery</measure>
    <time_frame>12 hours</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Number of participants with genital tract injuries</measure>
    <time_frame>2 hours</time_frame>
    <description>genital tract injuries:&#xD;
Perineal tears&#xD;
Vaginal tears&#xD;
Cervical tears&#xD;
Perineal hematomas&#xD;
Vaginal hematomas&#xD;
Uterine rupture</description>
  </other_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">250</enrollment>
  <condition>Prolonged First Stage of Labor</condition>
  <arm_group>
    <arm_group_label>Metoclopramide</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Intravenous injection of 10mg metoclopramide</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Intravenous injection of 0.9% sodium chloride</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Metoclopramide</intervention_name>
    <description>Intravenous injection of 10mg metoclopramide, at enrollment, then every 2 hours.&#xD;
Maximum of 3 doses.</description>
    <arm_group_label>Metoclopramide</arm_group_label>
    <other_name>Primperan (Trademark)</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Intravenous injection of 0.9% sodium chloride, at enrollment, then every 2 hours.&#xD;
Maximum of 3 doses.</description>
    <arm_group_label>Placebo</arm_group_label>
    <other_name>Normal saline</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Primigravida&#xD;
&#xD;
          -  Singleton pregnancy&#xD;
&#xD;
          -  Term gestation i.e. 37- 42 weeks&#xD;
&#xD;
          -  Sure reliable dates&#xD;
&#xD;
          -  Vertex presentation, occipitoanterior position&#xD;
&#xD;
          -  Spontaneous onset of labor&#xD;
&#xD;
          -  Regular uterine contractions at every 5 min ,each lasting for 20 sec&#xD;
&#xD;
          -  Cervical dilatation of 3-5cm&#xD;
&#xD;
          -  With or without rupture of membranes&#xD;
&#xD;
          -  No evidence of maternal or fetal distress&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Mal-presentations&#xD;
&#xD;
          -  Mal-positions&#xD;
&#xD;
          -  Multifetal pregnancy&#xD;
&#xD;
          -  Cephalopelvic disproportion&#xD;
&#xD;
          -  history of cervical surgery or injury&#xD;
&#xD;
          -  Hypersensitivity to metoclopramide&#xD;
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>35 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Mohamed I Ellaithy, MD</last_name>
    <role>Study Director</role>
    <affiliation>Ain Shams University</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Labor and delivery ward of Armed Forces Hospital, Southern Region.</name>
      <address>
        <city>Khamis Mushait</city>
        <zip>101</zip>
        <country>Saudi Arabia</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Saudi Arabia</country>
  </location_countries>
  <verification_date>March 2017</verification_date>
  <study_first_submitted>September 1, 2013</study_first_submitted>
  <study_first_submitted_qc>September 4, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 9, 2013</study_first_posted>
  <last_update_submitted>March 9, 2017</last_update_submitted>
  <last_update_submitted_qc>March 9, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">March 10, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Ain Shams University</investigator_affiliation>
    <investigator_full_name>Mohamed Ellaithy</investigator_full_name>
    <investigator_title>Lecturer of Obstetrics &amp; Gynecology</investigator_title>
  </responsible_party>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Metoclopramide</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

